» Articles » PMID: 30205401

Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and Without Cardiorenal Syndrome Type 1

Overview
Journal Cardiorenal Med
Publisher Karger
Date 2018 Sep 12
PMID 30205401
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiorenal syndrome type 1 (CRS type 1) is characterized by a rapid worsening of cardiac function leading to acute kidney injury (AKI). Inflammation and oxidative stress seem to play a pivotal role in its pathophysiology. In this in vivo study, we examined the putative role of inflammation and humoral markers in the pathogenesis of the CRS type 1.

Methods: We enrolled 53 patients with acute heart failure (AHF); 17 of them developed AKI (CRS type 1). The cause of AKI was presumed to be related to cardiac dysfunction after having excluded other causes. We assessed the plasma levels of proinflammatory cytokines (TNF-α, IL-6, IL-18, sICAM, RANTES, GMCSF), oxidative stress marker (myeloperoxidase, MPO), brain natriuretic peptide (BNP), and neutrophil gelatinase-associated lipocalin (NGAL) in AHF and CRS type 1 patients.

Results: We observed a significant increase in IL-6, IL-18, and MPO levels in CRS type 1 group compared to AHF (p < 0.001). We found higher NGAL at admission in the CRS type 1 group compared to the AHF group (p = 0.008) and a positive correlation between NGAL and IL-6 (Spearman's rho = 0.45, p = 0.003) and between IL-6 and BNP (Spearman's rho = 0.43, p = 0.004). We observed lower hemoglobin levels in CRS type 1 patients compared to AHF patients (p < 0.05) and inverse correlation between hemoglobin and cytokines (IL-6: Spearman's rho = -0.38, p = 0.005; IL-18: Spearman's rho = -0.32, p = 0.02).

Conclusion: Patients affected by CRS type 1 present increased levels of proinflammatory cytokines and oxidative stress markers, increased levels of tissue damage markers, and lower hemoglobin levels. All these factors may be implicated in the pathophysiology of CRS type 1 syndrome.

Citing Articles

The Role of Oxidative Stress as a Mechanism in the Pathogenesis of Acute Heart Failure in Acute Kidney Injury.

Tasic D, Dimitrijevic Z Diagnostics (Basel). 2024; 14(18).

PMID: 39335773 PMC: 11431490. DOI: 10.3390/diagnostics14182094.


Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients With End-Stage Renal Disease.

Karumanchi P, Sridharan D, Hoppensteadt D, Siddiqui F, Fareed J, Bansal V Clin Appl Thromb Hemost. 2024; 30:10760296241263101.

PMID: 38863224 PMC: 11179552. DOI: 10.1177/10760296241263101.


From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease.

Yeh T, Tu K, Wang H, Chen J Int J Mol Sci. 2024; 25(3).

PMID: 38339031 PMC: 10855633. DOI: 10.3390/ijms25031755.


From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge.

Zhang J, Zhu P, Li S, Gao Y, Xing Y Front Pharmacol. 2023; 14:1291922.

PMID: 38074146 PMC: 10703173. DOI: 10.3389/fphar.2023.1291922.


Inflammation in acute heart failure.

Garofalo M, Corso R, Tomasoni D, Adamo M, Lombardi C, Inciardi R Front Cardiovasc Med. 2023; 10:1235178.

PMID: 38045909 PMC: 10690826. DOI: 10.3389/fcvm.2023.1235178.


References
1.
Berke E, Morden N . Medical management of obesity. Am Fam Physician. 2000; 62(2):419-26. View

2.
Gullestad L, Aass H, Fjeld J, Wikeby L, Andreassen A, Ihlen H . Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001; 103(2):220-5. DOI: 10.1161/01.cir.103.2.220. View

3.
McNamara D, Holubkov R, Starling R, Dec G, Loh E, Torre-Amione G . Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103(18):2254-9. DOI: 10.1161/01.cir.103.18.2254. View

4.
Anker S, Coats A . How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002; 86(2-3):123-30. DOI: 10.1016/s0167-5273(02)00470-9. View

5.
Means Jr R . Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003; 2(2):116-21. View